Wiley announced Tuesday in an SEC filing that ceo Stephen Smith‘s urological cancer has recurred, and he “will be taking a period of medical leave in order to focus on treatment.” In September 2011 the company had first reported that Smith underwent “successful surgery” and was receiving “preventive chemotherapy.” Mark Allin‘s previously announced promoted to chief operating officer has been accelerated, and the company’s executive leadership team now reports to him (and Allin will report to the board’s executive committee).
